Active, not recruitingNo phase
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Russia15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 107 people enrolled
- Started
- 26 Jul 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Secukinumab
- Record updated
- 16 April 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients who provide written informed consent form (ICF) to participate in the study
- Male and female
- ≥ 18 years old
- Diagnosis of moderate or severe HS (Hurley stage and IHS4)
- Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF
- Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation
Who cannot take part
- Patients who received any vaccine within 4 weeks prior to secukinumab initiation
- Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making
- Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex)
- Clinically significant infection exacerbation, including active tuberculosis
- Patients with active inflammatory bowel disease (IBD)
- Age <18 years
- Participation in an ongoing clinical trial
- Pregnancy and breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).
The group in the trial
- Secukinumab
Patients prescribed with secukinumab in the treatment of Hidradenitis Suppurativa
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)
- Record updated
- 16 April 2026